Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Healthcare Biotechnology
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Sirona Biochem Corp > I'm surprised there hasn't been more discussion about this..
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(41)
•••
Comment by Alex1726on Jan 26, 2024 6:31pm
122 Views
Post# 35848018

RE:RE:RE:RE:RE:RE:I'm surprised there hasn't been more discussion about this..

RE:RE:RE:RE:RE:RE:I'm surprised there hasn't been more discussion about this..
How much money SBM HAS INVESTED so far to develop TFC 1326 AND how much money a partner will invest to bring it to market place? Based on this we can determine what is the real % of each part but SBM SHAREHOLDER NEEDS TO BE COMPENSATE FOR THE RISK THEY TOOK DEVELOPPING TFC 1326 , SO SUPPOSE IT COST $10M TO EXISTING SHAREHOLDERS ANS THE PARTNER PUT $10M IT CAN'T BE A 50%-50% JV.

What is the concern about a bankruptcy??? i don't get it.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities